IPO Launch Details

Mankind Pharma Limited has been a noteworthy name in the pharmaceutical industry. The company launched its IPO on May 8, 2023. The issue price ranged from Rs 1,020 to Rs 1,026 per equity share. The IPO was well-received in the market, given the company’s robust growth and widespread customer base.

Current Share Price

At the time of writing this article, Mankind Pharma Limited’s share price stands at approximately Rs 1,250 per share. The company’s stock has shown a positive trend since its debut in the stock market, making it an attractive option for both long-term and short-term investors.

Products Offered by Mankind Pharma Limited

Mankind Pharma Limited’s product portfolio spans multiple therapeutic categories, catering to diverse healthcare needs. Key products include:

• Pharmaceuticals: Wide range of prescription medicines.
• Consumer Healthcare Products: Over-the-counter medicines and wellness products.
• Generic Medicines: Affordable alternatives to branded medicines.
• Diagnostics: Comprehensive diagnostic solutions for various medical conditions.

Financial Details of the Company

Mankind Pharma Limited has demonstrated consistent financial performance over the years. For the fiscal year ending March 2023, here are some key financial metrics:

• Revenue: Rs 5,829.56 crore
• Net Profit: Rs 1,293.89 crore
• EBITDA Margin: 27.5%
• EPS (Earnings Per Share): Rs 34.6

The company’s strong financial health and continuous growth trajectory make it a reliable choice for investors.

Investment Value Calculation

If you had invested Rs 10,000 in Mankind Pharma Limited five years ago, let’s see how much it would be worth today.

Assuming the company’s stock had a compounded annual growth rate (CAGR) of 25% over the past five years, your investment would grow as follows:

Future Value = Rs 10,000 x (1 + 0.25)^5 = Rs 30,517.19

Therefore, an initial investment of Rs 10,000 would be approximately worth Rs 30,517 today, highlighting the company’s strong performance and growth potential.

Mankind Pharma Limited continues to be a promising player in the pharmaceutical industry, driven by its commitment to quality healthcare and solid financial performance. Investors who have believed in the company’s vision are reaping substantial returns, making it a stock worth considering for your portfolio.

We hope this comprehensive overview has provided valuable insights into Mankind Pharma Limited and its market potential. Stay tuned for more updates and investment tips!